Johnson & Johnson (NYSE:JNJ) Price Target Raised to $285.00

Johnson & Johnson (NYSE:JNJ) had its price objective boosted by JPMorgan Chase & Co. from $270.00 to $285.00 in a research report report published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other analysts have also issued reports on JNJ. TD Cowen boosted their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Guggenheim lifted their target price on Johnson & Johnson from $270.00 to $287.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, September 22nd. Finally, Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.87.

Johnson & Johnson Trading Down 2.2%

NYSE JNJ opened at $258.81 on Tuesday. The stock has a market cap of $623.70 billion, a PE ratio of 29.99, a PEG ratio of 2.60 and a beta of 0.21. Johnson & Johnson has a 12 month low of $182.94 and a 12 month high of $281.07. The company’s 50-day moving average price is $266.52 and its 200-day moving average price is $248.31. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of institutional investors have recently bought and sold shares of JNJ. Roxbury Financial LLC grew its position in Johnson & Johnson by 1.3% during the 3rd quarter. Roxbury Financial LLC now owns 4,822 shares of the company’s stock worth $1,277,000 after purchasing an additional 60 shares during the last quarter. Stonebridge Financial Group LLC raised its holdings in shares of Johnson & Johnson by 1.3% in the third quarter. Stonebridge Financial Group LLC now owns 38,550 shares of the company’s stock worth $10,206,000 after buying an additional 487 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 5.7% during the second quarter. QRG Capital Management Inc. now owns 440,815 shares of the company’s stock worth $111,954,000 after buying an additional 23,837 shares during the period. Security National Bank of Sioux City Iowa IA grew its holdings in shares of Johnson & Johnson by 27.2% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 18,143 shares of the company’s stock valued at $4,608,000 after buying an additional 3,878 shares during the last quarter. Finally, Reynders McVeigh Capital Management LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company’s stock valued at $19,432,000 after buying an additional 499 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target for J&J, citing growth prospects and pipeline strength. Analysts are also preparing for the company’s October 13 earnings report, with positive data for Tremfya and Carvykti supporting a generally bullish outlook. BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
• Positive Sentiment: J&J remains attractive to income-focused investors after raising its dividend for the 64th consecutive year. Recent coverage highlights its profitability, strong operating moat and ability to offset STELARA’s loss of exclusivity and biosimilar erosion with broader revenue growth. Why Johnson & Johnson Is a Great Dividend Stock Right Now
• Positive Sentiment: New IMAAVY data in adolescent generalized myasthenia gravis showed sustained disease control, reduced corticosteroid reliance and no new safety signals, potentially strengthening J&J’s immunology portfolio. Johnson & Johnson Shares in Focus After New Adolescent gMG Data
• Neutral Sentiment: A global J&J survey found that many women do not associate menopause-related eye-health changes with menopause. The initiative may support awareness of eye-care needs, but it is not an immediate earnings catalyst. New Global Survey by Johnson & Johnson
• Negative Sentiment: Valuation remains a concern: J&J has gained roughly 43% to 52% over the past year and is near a record, while comparison coverage describes the stock as trading at a substantial premium to some alternatives. That limits the margin for error ahead of earnings.
• Negative Sentiment: Investors continue to monitor patent cliffs and biosimilar pressure, particularly following STELARA’s exclusivity loss. Dividend-focused comparisons also warn that pharmaceutical patent expirations could pressure future growth and payout confidence.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.